XOMA Royalty

XOMA · NASDAQ

Price unavailable right now.

No price history for this range.

EPS: actual vs estimate

Beat the estimate in 5 of the last 8 quarters, by 580.6% on average

Reported EPS
Estimated EPS
XOMA earnings per share by quarter
QuarterEstimateReportedSurprise
Q1 FY26$0.1734-$0.03−117.3%
Q4 FY25-$0.1581$0.26+264.5%
Q3 FY25-$0.0408$0.70+1815.7%
Q2 FY25-$0.2251$0.44+295.5%
Q1 FY25-$0.3046$0.06+119.7%
Q4 FY24-$0.3094-$0.45−45.4%
Q3 FY24-$0.4454-$1.59−257.0%
Q2 FY24-$0.273$0.84+407.7%

Earnings calls

  • Ligand Pharmaceuticals Incorporated, XOMA Royalty Corporation - M&A Call
  • XOMA - Earnings call Q4 2025
  • Shareholder/Analyst Call - XOMA Corporation
  • Shareholder/Analyst Call - XOMA Corporation
  • Shareholder/Analyst Call - XOMA Corporation
  • 2018 UBS Global Healthcare Conference
  • Shareholder/Analyst Call - XOMA Corporation
  • UBS Global Healthcare Conference 2017

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.